{
  "ticker": "BOD",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02972820",
  "id": "02972820",
  "pages": 26,
  "price_sensitive": true,
  "date": "20250725",
  "time": "1540",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250725/pdf/06m4qcz45c7bpz.pdf",
  "summary": "### Material Information Summary:  \n\n#### **Financial & Operational Highlights (Appendix 4D - Half-Year Report)**  \n- **Revenue**: $600,659 (\u219138% YoY), driven by THC product sales ($380,587).  \n- **Net Loss**: ($16,434) (\u219399.7% YoY).  \n- **Cash Balance**: $597,896 (net cash $136,578 after overdraft).  \n- **Key Driver**: Shift from CBD to THC products; legacy OTC sales discontinued.  \n\n#### **Deed of Company Arrangement (DOCA) Update**  \n- **Status**: DOCA extended to **7 August 2025** (pending shareholder/ASX approval).  \n- **Pending Resolution**: Shareholder vote on Biortica acquisition (backdoor listing) by **30 September 2025**.  \n- **Funding**: Biortica covering DOCA costs; $591,446 received in H1 2024.  \n\n#### **Post-Reporting Date Events**  \n- **R&D Tax Incentive**: $627,279 received (May 2025).  \n- **Aqua Phase Subsidiary**: Dissolved (10 Dec 2024).  \n\n#### **Capital Structure**  \n- **Net Tangible Liabilities**: ($5.45M) or ($0.03 per share).  \n- **Shares Outstanding**: 177.3M (no change).  \n\n#### **Key Risk**  \nMaterial uncertainty over going concern if DOCA/shareholder approval fails.  \n\n**Format Notes**: Excluded boilerplate, director names, and non-material accounting details. Focused on liquidity, capital structure, and trading-relevant updates.",
  "usage": {
    "prompt_tokens": 13044,
    "completion_tokens": 344,
    "total_tokens": 13388,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-25T06:05:47.487504"
}